Literature DB >> 16301885

The clinical utility of inhalational anesthesia with sevoflurane in electroconvulsive therapy.

Keith G Rasmussen1, Thomas N Spackman, W Michael Hooten.   

Abstract

Anesthesia in electroconvulsive therapy (ECT) almost always is induced with intravenous agents, typically barbiturates, etomidate, or propofol. There are, however, circumstances in which an inhalational agent would be preferable for induction of general anesthesia. These uncommon clinical scenarios include severe needle stick phobia, agitation preventing insertion of an intravenous catheter, and poor tolerance of intravenous induction agents. Among the inhalational agents available, sevoflurane has several properties that make it the most desirable. In this case series, we describe several patients in our ECT practice in whom inhalational induction of general anesthesia with sevoflurane was deemed appropriate. In all patients, this method was well tolerated and offered distinct advantages compared with an intravenous induction agent. We conclude that ECT practitioners should keep this option in mind for select patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16301885     DOI: 10.1097/01.yct.0000180469.30712.90

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  3 in total

Review 1.  [Anaesthesiological aspects of electroconvulsive therapy].

Authors:  U Grundmann; M Oest
Journal:  Anaesthesist       Date:  2007-03       Impact factor: 1.041

2.  Effects of sevoflurane or ketamine on the QTc interval during electroconvulsive therapy.

Authors:  Feray Erdil; Zekine Begeç; Gülay Erdoğan Kayhan; Saim Yoloğlu; Mehmet Özcan Ersoy; Mahmut Durmuş
Journal:  J Anesth       Date:  2014-08-02       Impact factor: 2.078

3.  Impact of Sevoflurane and Thiopental Used Over the Course of Electroconvulsive Therapy: Propensity Score Matching Analysis.

Authors:  Taisuke Yatomi; Takahito Uchida; Akihiro Takamiya; Masataka Wada; Shun Kudo; Kazuki Nakajima; Hana Nishida; Bun Yamagata; Masaru Mimura; Jinichi Hirano
Journal:  Front Hum Neurosci       Date:  2022-07-08       Impact factor: 3.473

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.